Another U.S. Pharmaceutical Company Commences Unifill Stability...

Another U.S. Pharmaceutical Company Commences Unifill Stability Studies Aimed At Multiple Target Injectable Drugs

Target drugs include both late-stage pipeline and commercially approved drugs



YORK, Pa., Dec. 19, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today announced that another U.S. based pharmaceutical company has commenced stability and evaluation studies of the Unifill syringe for use with multiple injectable drugs.

The target drugs, which include both pipeline drugs as well as commercially approved drugs that will benefit from lifecycle extension, are high-value therapeutics for chronic diseases and require periodic injections. The customer is also reviewing other Unilife devices for use with additional injectable drugs in their portfolio.


Mr. Alan Shortall, CEO of Unilife, said: "The supply of Unifill syringes to this pharmaceutical customer for use with so many of their injectable drugs at one time is a major accomplishment. The customer cited the unique value proposition of the Unifill syringe, with its automatic, integrated and highly intuitive safety features, as a key factor in their selection process. This is not surprising given how attractive and differentiated the Unifill syringe is compared to conventional prefilled syringe technologies.

"The commercial value of the strong relationship we have established with this pharmaceutical customer should rapidly expand beyond near-term device sales as we formalize a series of clinical development agreements and commercial supply contracts. We expect to generate accelerating, incremental revenues with this customer moving forward, with peak annual demand of between 25 million and 35 million units of Unifill annually for their initial series of target drugs."

"This customer is just one of many pharmaceutical companies that are selecting our devices to enable or enhance the delivery and commercial success of their injectable therapies. As I stated during our recent Annual General Meeting, there is a tremendous amount of business activity now occurring across our commercial pipeline. In the last month alone, we have held meetings with senior executives from more than a dozen pharmaceutical companies as part of advanced, ongoing discussions that relate to every device platform across our portfolio. We look forward to announcing the formalization of many of these commercial relationships in the weeks and months ahead," Mr. Shortall concluded.